The global lateral flow assays market size was valued at USD 10.69 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.26% from 2023 to 2030. Lateral flow assays are used to detect the presence of a target component in the liquid sample without the need for expensive or specialized equipment. Rising prevalence of infectious diseases is anticipated to boost the lateral flow assays market growth during the forecast period. For instance, according to WHO, about 10 million people worldwide suffered from tuberculosis in 2020. Furthermore, new product approvals and increasing revenue due to the sales of COVID-19 rapid tests are driving the market growth. As of January 2022, the U.S. FDA had approved at least 12 rapid antigen at-home tests for detection of COVID-19, with companies such as Abbott Laboratories and Quidel Corporation being among the key players involved.
The COVID-19 pandemic has propelled the adoption of lateral flow assays due to a sharp rise in the demand for rapid, point-of-care testing of the deadly disease. As lateral flow assays represent a cost-effective, and easy-to-use testing solution for mitigation of COVID-19 outbreak, these assays are expected to witness significant demand for disease surveillance during the pandemic period.
Furthermore, international organizations, such as WHO and European Commission, as well as governments around the world have focused on mass population testing, followed by contact tracing, for curbing the spread of COVID-19. Lateral flow assays have enabled frequent testing and decentralization of healthcare for supporting large-scale testing efforts without the need for complex & extensive infrastructure.
Applications of lateral flow assays are significantly increasing globally. Public awareness campaigns aimed at identifying the symptoms of infectious diseases and ways to prevent them play an important role in controlling disease epidemics. Thus, increased patient awareness has led to high demand for lateral flow assays. Furthermore, new product approvals and increasing revenue due to the sales of COVID-19 rapid tests are driving the lateral flow assay market growth.
For instance, Abbott had shipped more than 1 billion COVID-19 tests since the beginning of the pandemic up to the end of the third quarter of 2021, and its sales for the quarter increased by 23.4% to USD 10.9 billion, including USD 1.9 billion revenue from sales of the tests. Similarly, in 2021, COVID-19 tests accounted for USD 510 million of Quidel’s fourth-quarter revenue of around USD 635 million.
Rapid detection of chronic diseases, especially infectious diseases, is necessary and should be accurate & affordable. It helps minimize the need for multiple patient visits and facilitates timely treatment & control of infectious disease outbreaks. The WHO has recommended prompt parasite-based diagnosis in all malaria-suspected patients before proper administration of treatment.
Thus, there is growing need for rapid diagnostic test kits, facilitating prompt diagnosis and treatment. According to WHO, rapid diagnostic tests are capable of significantly improving the quality of diagnosis and management of infectious diseases, especially in areas with restricted access to advanced technologies.
The use of lateral flow devices also eliminates the need to wait for deciphering test results as well as aids in the optimization of timely treatment decisions, improves efficacy of care provided, and significantly reduces diagnosis cost, especially in areas with resource-constrained settings and insufficient laboratory infrastructure. Rising trend of decentralized testing has been crucial in increasing the adoption of lateral flow devices globally. The role of these devices has also been observed in controlling major infectious diseases such as malaria and influenza.
According to WHO, rapid diagnostic tests are used in diagnosis by healthcare professionals distant from microscopy services; remote diagnosis by professionals in malaria-endemic countries; and outbreak investigation & survey of parasite prevalence. Thus, various benefits offered by lateral flow devices are among key factors responsible for increasing the adoption of lateral flow devices globally.
Moreover, rising prevalence of infectious diseases, including malaria, tuberculosis, HIV/AIDS, hepatitis, pneumonia, and influenza, is one of the major factors boosting the market growth. According to the World Malaria Report 2020, around 241 million malaria cases were reported in 2021, leading to over 627 thousand malaria-related deaths globally.
As per the data from the IDF Diabetes Atlas, there were about 537 million adults living with diabetes in 2021, and this number is anticipated to increase to 643 million by 2030. The disease is estimated to have caused 6.7 million deaths in 2021. Thus, with the rising incidence of chronic diseases, the demand for lateral flow assays is likely to increase in the coming years.
Based on the product segment, the kits and reagents larger revenue share of 67.81% in 2022 as these lateral flow kits enable greater adaptability to capture and detect any type of analyte without the requirement to spray the captured antibodies on the test strip. Due to their versatility, these kits are also used in pharmaceuticals, animal health, environmental testing, feed & food testing, and crop & plant testing. Launch of new kits by major players is anticipated to boost market growth during the forecast period. For instance, in July 2021, Abbott launched its Panbio COVID-19 Antigen Self-Test in India. Similarly, in January 2022, Roche Diagnostics India also launched its COVID-19 At-Home Test.
Lateral flow readers are also estimated to register considerable CAGR during the forecast period. The readers are cost efficient & easy to use and provide accurate results within a few minutes. Rise in strategic initiatives undertaken by market players are expected to boost the lateral flow assay market growth during the forecast period. For instance, in December 2021, Eurofins Technologies announced launch of its new RapidScan ST5-W lateral flow reader which is especially designed for environmental and food rapid tests.
Clinical testing segment held the largest share of 76.87% in 2022 owing to increase in the incidence of infectious diseases. Based on clinical testing, the market is sub-segmented into infectious diseases, cardiac marker testing, cholesterol/lipid testing, pregnancy & fertility testing, drugs of abuse testing, and other clinical testing. The demand for rapid diagnostic kits such as lateral flow assays is increasing due to rising risk of pathogen diseases and their exposure.
Lateral flow assay testing is used in clinical testing scenarios and multiple diagnostic industries due to ease of use & portability. These tests provide rapid results and are most commonly used for testing of infectious diseases, pregnancy, and urine analysis. In addition, as oral fluid-based testing is gradually developing, the use of lateral flow assays is becoming convenient because of the noninvasive nature of collecting specimen.
The drug development & quality testing segment is expected to grow at a fastest CAGR. Lateral flow assays are being increasingly used for therapeutic drug monitoring due to their ease of use, cost-effectiveness, and capacity to detect several markers in samples. Such assays find applications for attaining fully & semi-quantitative results in several less regulated and regulated industries.
Moreover, widespread availability of antibiotic tests is another factor driving the market growth during the forecast period. Charm Sciences Inc. offers Charm ROSA lateral flow assay, for the detection of aflatoxin M1 and some common antibiotics used for the treatment of dairy cows. These tests utilize patented technology to target drug sensitivities at safe & regulated levels, thereby, preventing unnecessary rejection of milk caused by extremely sensitive screening tests.
Sandwich assays are expected to hold the largest revenue share of 39.35% in 2022 owing to their accuracy, affordability, and ease of use. The test can also be used in low-resource healthcare settings, without the need for trained personnel. The format of sandwich assays is typically used for the detection of larger analytes, which have about two epitopes or binding sites.
For Instance, Abcam offers Universal Lateral Flow Assay Kit that enables the development of a custom sandwich assays by combining GOLD conjugation and Ulfa-Tag kit technologies. One of the advantages offered by such a kit is its flexibility to work with any pair of detection and capture antibodies. Thus, an increase in the availability of technologically advanced sandwich assays is expected to propel the lateral flow assays market growth.
The multiplex detection assays segment is expected to grow at the fastest CAGR during the study period. Increasing development of various multiplex lateral flow assays by research & academic centers is a major factor anticipated to influence market growth. For instance, recent development published in the ACS Omega journal in August 2021, involves the creation of a novel multiplex spot array named Blind Spot.
The assay is a six-plex assay consisting of test spots printed in 6 positions, along with a MACAW (Modular Automated Colorimetric Analysis Widget) sensor for analysis and interpretation of test result images. It overcomes the challenges encountered in capillary flow dynamics and design limitation involved in the development of assays with several horizontal test lines. Such advancements in the development of multiplex lateral flow assays are expected to boost their usage in the near future, thereby driving the segment growth.
The lateral flow immunoassay segment held the largest revenue share of 64.50% in 2022. In physician offices, hospitals, clinical laboratories, & clinics, lateral flow-based tests are used for the quantitative and qualitative detection of a wide variety of antibodies & antigens. It is an easy-to-perform and a low-cost analytical method used for screening, monitoring, & diagnosis of numerous diseases. Owing to such factors, the applicability of lateral flow immunoassays is very high; these can be used by any health staff and/or patients at home.
Nucleic acid lateral flow assay is set to grow at a significant pace over the forecast years. Currently, the lateral flow assay market is dominated by antibodies. However, several limitations of lateral flow immunoassays such as high inter-batch variations, error margin, and storage requirements of conventional antibody-based lateral flow assays has led to recent progress in nucleic acid lateral flow assays. In recent years, nucleic acid-based diagnostic tests have gained considerable attention.
Hospitals & clinics represent primary care setups, with majority of the population relying on them for diagnosis and treatment of various medical conditions. As a result, hospitals & clinics segment held the largest market share of 35.69% in 2022. Constant changes in healthcare industry have led to an increase in the need for hospitals with enhanced diagnostic services. Increase in healthcare expenditure globally has significantly contributed to the growth of the market.
Furthermore, various infectious diseases, such as influenza, HIV, and hepatitis, are easily transmitted in hospitals, often causing outbreaks. To reduce or even eliminate such occurrences, hospitals have to comply with specific guidelines to ensure adequate patient quarantine measures, safety of healthcare workers, and proper sanitization. These attributes can positively affect the market growth.
The pharmaceutical and biotechnology companies segment is projected to grow at fastest CAGR during the forecast period as these companies are involved in strategic initiatives, such as mergers & acquisitions, product development, product approvals & launches, and expansion of global operations. Emerging players in the market are undertaking several collaborations to enhance their offerings in lateral flow tests.
For instance, in March 2022, Abingdon Health plc and Vatic Health Limited signed a Memorandum of Understanding for the development and manufacturing of lateral flow tests for infectious diseases. An increase in such strategic collaborations is anticipated to boost development of lateral flow assays and contribute to segment growth during the forecast period.
North America accounted for the largest revenue share of 35.87% in 2022. Increased public awareness and rise in availability of a wide range of diagnostic tests fueled by the COVID-19 pandemic is expected to lead to significant growth in the segment. For instance, as of December 2021, there were about 300 million at-home, rapid tests for COVID-19 available in the U.S., which was tenfold higher than the 24 million tests available in August 2021. Moreover, the Biden Administration announced an investment of about USD 650 million in November 2021 for boosting rapid diagnostic testing and increasing the access to COVID-19 tests.
In addition, increasing number of new entrants and approvals in this domain are anticipated to boost the lateral flow assays market growth during the forecast period. For instance, in November 2021, InBios International, Inc. received Emergency Use Authorization (EUA) from the U.S. FDA for its SCoV-2 Ag Detect Rapid Self-Test, that can provide results within approximately 20 minutes.
Asia Pacific is expected to grow at a rapid CAGR owing to the increased collaborations among market entrants, initiatives undertaken by the government and key market players. In addition, increase in the number of awareness campaigns by leading market players is anticipated to fuel market growth.
For instance, the Indian Government’s National Strategic Plan (NSP) for Malaria Elimination (2017-2022) is taking efforts to increase awareness and eliminate malaria in the country by 2030. The plan, under the nation’s National Health Mission, is a part of National Vector Borne Disease Control Programme and is anticipated to have a budget of USD 106.53 billion.
Key players in the market are adopting various organic and inorganic strategies such as partnerships, mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in February 2023, Cambridge Molecular Diagnostics Limited launched a lateral flow test, SwiftDx. The test is used for the detection of mycoplasma contamination and is a easy to use rapid test providing results within minutes. This launch will result in high demand for lateral flow assays driving the market growth over the forecast period. Some of the key players in the global lateral flow assays market include:
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche AG
Bio-Rad Laboratories, Inc
Market size value in 2023
USD 10.16 billion
Revenue forecast in 2030
USD 13.60 billion
CAGR of 4.26% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, technique, test-type, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France, Italy, Spain, Russia; Sweden; Denmark; Norway; China; Japan; India; South Korea; Singapore; Thailand; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Abbott Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc, bioMérieux SA, Quidel Corporation, Hologic, Inc., PerkinElmer, Inc., Merck KGaA, BD, Siemens Healthineers, Danaher Corporation, QIAGEN N.V.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional and segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global lateral flow assay market report on the basis of product, application, technique, test-type, end-use, and region.
Kits & Reagents
Lateral Flow Readers
Lateral Flow Readers
Application Outlook (Revenue, USD Million, 2018 - 2030)
Infectious Disease Testing
Mosquito Borne Disease Testing
Sexually Transmitted Infection Testing
Other STI Testing
Other Infectious Diseases
Cardiac Marker Testing
Troponin I and T Testing
BNP and NT-Probnp Testing
Other Cardiac Marker Tests
Pregnancy & Fertility Testing
Cholesterol Testing/Lipid Profile
Drugs of Abuse Testing
Other Clinical Tests
Food Safety & Environment Testing
Drug Development & Quality Testing
Technique Outlook (Revenue, USD Million, 2018 - 2030)
Multiplex Detection Assays
Test-type Outlook (Revenue, USD Million, 2018 - 2030)
Lateral Flow Immunoassay
Nucleic Acid Lateral Flow Assay
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
b. The global lateral flow assays market size was estimated at USD 10.69 billion in 2022 and is expected to reach USD 10.16 billion in 2023.
b. The global lateral flow assays market is expected to grow at a compound annual growth rate of 4.26% from 2023 to 2030 to reach USD 13.60 billion by 2030.
b. Clinical testing dominated the lateral flow assays market with a share of 76.87% in 2022. This is attributable to the increase in various chronic and infectious diseases globally.
b. Some key players operating in the lateral flow assays market include Abbott; Quidel Corporation; Hologic Inc.; Thermo Fisher Scientific Inc.; F.Hoffmann-La Roche; Siemens AG; Danaher Corporation; Becton, Dickinson and Company; Bio-Rad; bioMerieux; and PerkinElmer.
b. Key factors that are driving the lateral flow assays market growth include the increase in demand for point of care testing and the rising incidence of infectious diseases is anticipated to result in demand for lateral flow assays globally.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.